1007882-73-6Relevant academic research and scientific papers
Hepatitis C virus NS5A replication complex inhibitors: The discovery of daclatasvir
Belema, Makonen,Nguyen, Van N.,Bachand, Carol,Deon, Dan H.,Goodrich, Jason T.,James, Clint A.,Lavoie, Rico,Lopez, Omar D.,Martel, Alain,Romine, Jeffrey L.,Ruediger, Edward H.,Snyder, Lawrence B.,Laurent, Denis R. St.,Yang, Fukang,Zhu, Juliang,Wong, Henry S.,Langley, David R.,Adams, Stephen P.,Cantor, Glenn H.,Chimalakonda, Anjaneya,Fura, Aberra,Johnson, Benjamin M.,Knipe, Jay O.,Parker, Dawn D.,Santone, Kenneth S.,Fridell, Robert A.,Lemm, Julie A.,O'Boyle, Donald R.,Colonno, Richard J.,Gao, Min,Meanwell, Nicholas A.,Hamann, Lawrence G.
, p. 2013 - 2032 (2014/04/03)
The biphenyl derivatives 2 and 3 are prototypes of a novel class of NS5A replication complex inhibitors that demonstrate high inhibitory potency toward a panel of clinically relevant HCV strains encompassing genotypes 1-6. However, these compounds exhibit
